Specifically, statistically significant MPMR elevations, with fold changes of 2.01, 1.36, and 2.61, were identified on the promoters of HOXA9, the HOXD3 genes of cancer patients, and the RASSF1A promoter of non-cancer patients, respectively (Table 6). This evidence concerns the gene HOXA9 and cancer.